Clinical trials: Adenocarcinoma
Hepatocellular Carcinoma, Hepatocellular Cancer
Characterization of Methylation Patterns in Hepatocellular Carcinoma
This study is being performed as part of the development process of the Liver EpiCheck test which includes the identification of different methylation profiles in HCC (hepatocellular carcinoma) patients compare to cancer free…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Cirrhosis
- Trial name
- NCT04264754
- Testing
- Blood collection
- Where
- 5 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Nucleix Ltd.
Gastric Adenocarcinoma, Advanced Solid Tumors
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, when administered as a single…
- Conditions
- Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03852251
- Testing
- AK104, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Akeso
Adenocarcinoma
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast
The primary objectives of this study were to assess the safety and tolerability of intravenously (i.v.) administered 186Rhenium (186Re)-labelled bivatuzumab and to investigate the biodistribution and pharmacokinetics of…
- Trial name
- NCT02204046
- Testing
- BIWA 4
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Lymphoma, Cancer
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
- Conditions
- Lymphoma, Cancer, Thyroid Carcinoma
- Trial name
- NCT00215605
- Testing
- XL184
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Exelixis
Colorectal Neoplasms
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression.
- Trial name
- NCT00313794
- Testing
- CP-675,206
- Where
- 11 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Advanced Adult Hepatocellular Carcinoma
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer worldwide and the third most common cause of death from cancer.
- Trial name
- G-202-003 (NCT01777594)
- Testing
- G-202
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- GenSpera, Inc.
Pancreatic Cancer
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with…
- Trial name
- NCT00099294
- Testing
- Glufosfamide
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 300 people
- Sponsor
- Threshold Pharmaceuticals
Metastatic Pancreatic Adenocarcinoma
Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
This trial will assess the safety and tolerability of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy.
- Trial name
- NCT05102721
- Testing
- Avelumab and Pepinemab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Vaccinex Inc.
Ovarian Cancer, Merkel Cell Carcinoma
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Ovarian Cancer, Merkel Cell Carcinoma, SCLC
- Trial name
- NCT00346385
- Testing
- BB-10901
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 97 people
- Sponsor
- ImmunoGen, Inc.
Colorectal Cancer Screening, Colorectal Cancer Metastatic
Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test
The Mainz Biomed Colorectal Cancer Screening Test is being studied for its performance in the identification of the presence of colorectal cancer (CRC) or advanced adenoma (AA) in the colon in patients at average risk for…
- Conditions
- Colorectal Cancer Screening, Colorectal Cancer Metastatic, Colon Adenocarcinoma
- Trial name
- eAArly DETECT (NCT06864338)
- Where
- United States
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Mainz Biomed
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
- Conditions
- Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- PRESERVE-004 (NCT05446298)
- Testing
- ONC-392, Pembrolizumab
- Where
- 21 sites in United States
- Volunteers
- 58 people
- Sponsor
- OncoC4, Inc.
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- CANFOUR (NCT03267316)
- Testing
- CAN04, Cisplatin, Gemcitabine
- Where
- 25 sites in Austria, Belgium and 9 more
- Volunteers
- 167 people
- Sponsor
- Cantargia AB
Advanced Solid Tumours
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain Fragment variable (scFv) format directed…
- Trial name
- NCT01058538
- Testing
- L19IL2
- Where
- 2 sites in Germany, Italy
- Volunteers
- 33 people
- Sponsor
- Philogen S.p.A.
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Hepatocellular Carcinoma, Liver Cancer
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
This is a open-label, dose escalation, multi-center, Phase I / Phase II study to assess the safety of an autologous T-cell product (ET140202) in adult subjects with advanced Alpha-fetoprotein (AFP) positive/Human Leukocyte…
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer
- Trial name
- ET-109 (NCT03998033)
- Testing
- ET140202 autologous T cell product
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Eureka Therapeutics Inc.
Adenocarcinoma of the Lung
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
This is a Phase II clinical trial evaluating the benefit from therapy with vintafolide in participants with progressive adenocarcinoma of the lung.
- Trial name
- NCT00511485
- Testing
- Vintafolide, Etarfolatide
- Volunteers
- 43 people
- Sponsor
- Endocyte
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese…
- Conditions
- Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer
- Trial name
- ZIRDOSE-CP (NCT05861778)
- Testing
- 89Zr-Girentuximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Pancreatic Cancer
Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
The drug for this submission is Hope Biosciences' allogeneic, first blood relative, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Pancreatic Cancer (PC).
- Trial name
- NCT04087889
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences LLC
Advanced Solid Tumors, Hematologic Neoplasms
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with…
- Conditions
- Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors
- Trial name
- NCT03219268
- Testing
- tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 277 people
- Sponsor
- MacroGenics